Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06966024 · ClinicalTrials.gov registry record · Phase 1
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
A Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT06966024 is a Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 60 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06966024, a Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Conditions Studied
Interventions
- DRUG DCC-2812
Study Locations (3)
Texas
- NEXT Oncology, Austin - Austin
- NEXT Oncology, San Antonio - San Antonio
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06966024
The ClinicalTrials.gov registry entry for NCT06966024 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which DCC-2812 is the first listed.
NCT06966024 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06966024 about?
NCT06966024 is a clinical study titled "Study of DCC-2812 in Participants With Advanced Genitourinary Cancers". This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
What is the current status of trial NCT06966024?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-08-27. Estimated completion is 2029-02.
What conditions does trial NCT06966024 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT06966024?
The interventions under investigation include: DCC-2812 (DRUG).
Who is sponsoring clinical trial NCT06966024?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06966024 being conducted?
This trial has 3 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.